NKTR (Nektar Therapeutics) Float Percentage Of Total Shares Outstanding : 78.43% (As of Mar. 23, 2025)

View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nektar Therapeutics's float shares is 145.96 Mil. Nektar Therapeutics's total shares outstanding is 186.10 Mil. Nektar Therapeutics's float percentage of total shares outstanding is 78.43%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nektar Therapeutics's Insider Ownership is 2.85%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nektar Therapeutics's Institutional Ownership is 72.30%.

Nektar Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Nektar Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	145.96	/	186.10
	=	78.43%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (NAS:NKTR) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

NKTR:Mexico 0UNL:UK ITH:Germany ITH:Germany

Address

455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158

Website

https://www.nektar.com

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Executives

Howard W Robin	director, officer: President & CEO
Jonathan Zalevsky	officer: Chief R&D Officer	455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Mark Andrew Wilson	officer: SVP & General Counsel	1613 RAY DRIVE, BURLINGAME CA 94010
Robert Chess	director, officer: Executive Chairman
Myriam Curet	director	1020 KIFER ROAD, SUNNYVALE CA 94086
Jeffrey Robert Ajer	director	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Sandra A. Gardiner	officer: Chief Financial Officer	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jillian B. Thomsen	officer: VP & Chief Accounting Officer	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Karin Eastham	director	C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Gil M Labrucherie	officer: SVP, COO & CFO	150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
John Northcott	officer: SVP & Chief Commercial Officer	455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Diana Brainard	director	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
R Scott Greer	director	6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253
Lutz Lingnau	director	15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945
Stephen K Doberstein	officer: Chief Scientific Officer	129 ELSIE STREET, SAN FRANCISCO CA 94110